News & Blog

NBTS Brain Tumor Clinical Trials Report: Q4 2020

It can be hard to keep track of new clinical trial opportunities opening across the United States, especially during the current public health crisis created by the coronavirus (COVID-19). However, there are many clinical trials still actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and contact the party responsible for enrolling patients, just follow the hyperlink.**


  • Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients
    • Brief Description: This is a single-arm trial to examine the feasibility of a mobile health application, Elly, to reduce levels of anxiety, stress, loneliness, and social isolation in cancer patients and survivors (including brain cancer patients). Participants will be given access to the Elly phone application and will be asked to complete questionnaires measuring quality of life at multiple timepoints during the study.
  • Study of Pamiparib in Newly Diagnosed and Recurrent GBM
    • Brief Description: This is a phase 0/II study that will enroll up to 30 participants with newly diagnosed and recurrent glioblastoma. The trial will be composed of a phase 0 component (subdivided into Arm A, Arm B, and Arm C), and an exploratory phase II component. Participants with tumors demonstrating a response in the phase 0 component of the study will graduate to an exploratory phase II trial that combines therapeutic dosing of pamiparib plus fractionated radiotherapy (for unmethylated MGMT promoter newly-diagnosed cases), pamiparib plus fractionated radiotherapy (for recurrent cases), or olaparib plus fractionated radiotherapy (recurrent cases).
  • Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
    • Brief Description: This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype, historically lower-grade gliomas or non-histological molecular glioblastomas. The goal of this clinical research study is to compare receiving new radiation therapy doses and volumes to the prior standard treatment for patients with historically grade II or grade III IDH wild-type gliomas, which may now be referred to as IDH wildtype molecular glioblastomas at some institutions. 
  • Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma
    • Brief Description: A phase o trial of ascending energy doses of sonodynamic therapy (SDT) utilizing the MRgFUS combined with intravenous (IV) aminolevulinic acid HCl (ALA) to assess safety and efficacy in up to 30 participants with recurrent high-grade glioma. Eligible participants who are scheduled for resection will be administered IV ALA approximately six to seven (6-7) hours prior to receiving SDT.
  • Ommaya Reservoir Placement for Brain Tumor Biomarker Access
    • Brief Description: The purpose of this trial is to determine the safety and feasibility of intra-operative Ommaya Reservoir placement during a clinically indicated operation for a brain tumor. The Ommaya reservoir will facilitate longitudinal access to cerebrospinal fluid (CSF) for analysis of potential biomarkers for brain tumor research and individualized monitoring.
    • Associated study

Below is a list of phase III clinical trials that are currently enrolling patients as recorded at the close of 2020. A phase III clinical trial is traditionally the last, pivotal step in the evaluation of a potential new medicine before it is approved for use by all patients with the indicated disease.

Many of these are trials of a “novel/investigational agent” – meaning it is the first time a particular treatment is being tried for brain tumor patients. There are also a number of trials with therapies already in use for some brain tumor patients, for which researchers are evaluating these existing treatments in different combinations, different dosing regimens, and/or specific subgroups of patients.

Phase III Clinical Trials with Novel/Investigational Agents

Phase III Clinical Trials with Prior/Known Agents


*For a more comprehensive list of ALL open brain tumor clinical trials, visit the NBTS Clinical Trial Finder at trials.braintumor.org, where you can search potential opportunities for enrollment based on criteria important and specific to you.

**For additional navigation support, you can access NBTS’s Personalized Support and Navigation program by emailing patientnavigator@braintumor.org. Our Patient Navigator, Mary Lovely, PhD, RN, CNRN, has more than 30 years of experience working closely with brain tumor patients and families as a neurological nurse, clinical nurse specialist, and research nurse. To learn more visit here.

Post a Comment

Your email is kept private. Required fields are marked *

Share